TY - JOUR
T1 - Prothrombin kringle-2
T2 - A potential inflammatory pathogen in the parkinsonian dopaminergic system
AU - Leem, Eunju
AU - Jeong, Kyoung Hoon
AU - Won, So Yoon
AU - Shin, Won Ho
AU - Kim, Sang Ryong
N1 - Publisher Copyright:
© Experimental Neurobiology 2016.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Although accumulating evidence suggests that microglia-mediated neuroinflammation may be crucial for the initiation and progression of Parkinson's disease (PD), and that the control of neuroinflammation may be a useful strategy for preventing the degeneration of nigrostriatal dopaminergic (DA) projections in the adult brain, it is still unclear what kinds of endogenous biomolecules initiate microglial activation, consequently resulting in neurodegeneration. Recently, we reported that the increase in the levels of prothrombin kringle-2 (pKr-2), which is a domain of prothrombin that is generated by active thrombin, can lead to disruption of the nigrostriatal DA projection. This disruption is mediated by neurotoxic inflammatory events via the induction of microglial Toll-like receptor 4 (TLR4) in vivo, thereby resulting in less neurotoxicity in TLR4-deficient mice. Moreover, inhibition of microglial activation following minocycline treatment, which has anti-inflammatory activity, protects DA neurons from pKr- 2-induced neurotoxicity in the substantia nigra (SN) in vivo . We also found that the levels of pKr-2 and microglial TLR4 were significantly increased in the SN of PD patients compared to those of age-matched controls. These observations suggest that there may be a correlation between pKr-2 and microglial TLR4 in the initiation and progression of PD, and that inhibition of pKr-2- induced microglial activation may be protective against the degeneration of the nigrostriatal DA system in vivo . To describe the significance of pKr-2 overexpression, which may have a role in the pathogenesis of PD, we have reviewed the mechanisms of pKr-2- induced microglial activation, which results in neurodegeneration in the SN of the adult brain.
AB - Although accumulating evidence suggests that microglia-mediated neuroinflammation may be crucial for the initiation and progression of Parkinson's disease (PD), and that the control of neuroinflammation may be a useful strategy for preventing the degeneration of nigrostriatal dopaminergic (DA) projections in the adult brain, it is still unclear what kinds of endogenous biomolecules initiate microglial activation, consequently resulting in neurodegeneration. Recently, we reported that the increase in the levels of prothrombin kringle-2 (pKr-2), which is a domain of prothrombin that is generated by active thrombin, can lead to disruption of the nigrostriatal DA projection. This disruption is mediated by neurotoxic inflammatory events via the induction of microglial Toll-like receptor 4 (TLR4) in vivo, thereby resulting in less neurotoxicity in TLR4-deficient mice. Moreover, inhibition of microglial activation following minocycline treatment, which has anti-inflammatory activity, protects DA neurons from pKr- 2-induced neurotoxicity in the substantia nigra (SN) in vivo . We also found that the levels of pKr-2 and microglial TLR4 were significantly increased in the SN of PD patients compared to those of age-matched controls. These observations suggest that there may be a correlation between pKr-2 and microglial TLR4 in the initiation and progression of PD, and that inhibition of pKr-2- induced microglial activation may be protective against the degeneration of the nigrostriatal DA system in vivo . To describe the significance of pKr-2 overexpression, which may have a role in the pathogenesis of PD, we have reviewed the mechanisms of pKr-2- induced microglial activation, which results in neurodegeneration in the SN of the adult brain.
KW - Microglia
KW - Parkinson's disease
KW - Prothrombin kringle-2
KW - Toll-like receptor 4
UR - http://www.scopus.com/inward/record.url?scp=84995582124&partnerID=8YFLogxK
U2 - 10.5607/en.2016.25.4.147
DO - 10.5607/en.2016.25.4.147
M3 - Article
AN - SCOPUS:84995582124
SN - 1226-2560
VL - 25
SP - 147
EP - 155
JO - Experimental Neurobiology
JF - Experimental Neurobiology
IS - 4
ER -